0000905718-18-000995.txt : 20181227 0000905718-18-000995.hdr.sgml : 20181227 20181227160847 ACCESSION NUMBER: 0000905718-18-000995 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181221 FILED AS OF DATE: 20181227 DATE AS OF CHANGE: 20181227 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sinclair Andrew CENTRAL INDEX KEY: 0001762451 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36593 FILM NUMBER: 181254785 MAIL ADDRESS: STREET 1: C/O SOLENO THERAPEUTICS INC. STREET 2: 1235 RADIO ROAD, SUITE 110 CITY: REDWOOD CITY STATE: CA ZIP: 94065 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SOLENO THERAPEUTICS INC CENTRAL INDEX KEY: 0001484565 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 770523891 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1235 RADIO ROAD STREET 2: SUITE 110 CITY: REDWOOD CITY STATE: CA ZIP: 94065 BUSINESS PHONE: 650-213-8444 MAIL ADDRESS: STREET 1: 1235 RADIO ROAD STREET 2: SUITE 110 CITY: REDWOOD CITY STATE: CA ZIP: 94065 FORMER COMPANY: FORMER CONFORMED NAME: Capnia, Inc. DATE OF NAME CHANGE: 20100219 4 1 soleno_fm4dec212018.xml X0306 4 2018-12-21 0 0001484565 SOLENO THERAPEUTICS INC SLNO 0001762451 Sinclair Andrew C/O SOLENO THERAPEUTICS INC. 1235 RADIO ROAD, SUITE 110 REDWOOD CITY CA 94065 1 0 0 0 Common Stock 2018-12-21 4 P 0 4669272 1.60 A 4669272 I See Footnotes Warrant 2.00 2018-12-21 4 P 0 4669272 .0062 A 2018-12-21 2023-12-21 Common Stock $.001 par value 233463 4669272 I See Footnotes Stock Option (right to buy) 1.57 2018-12-21 4 A 0 20000 0 A 2028-12-21 Common Stock $.001 par value 20000 20000 D Shares are held by Abingworth Bioventures VII, LP ("ABV VII"). Abingworth LLP is the investment manager of ABV VII and has been delegated with all investment and dispositive power over the securities held by ABV VII. Reporting Person is a Partner and Portfolio Manager of Abingworth LLP. An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VII. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VII to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. This option was granted on December 21, 2018 with respect to 20,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning on December 21, 2018. /s John Heard, as attorney-in-fact 2018-12-27